Research programme: pifithrin compounds - Quark Pharmaceuticals
Alternative Names: Oncology research programme - Quark; PFT; PFT-X; PFT-β; QG-AGC1; QG-AGC6Latest Information Update: 02 Oct 2021
At a glance
- Originator Quark Biotech
- Developer Quark Pharmaceuticals
- Class Small molecules
- Mechanism of Action Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alopecia
Most Recent Events
- 10 Mar 2005 Quark is actively seeking strategic partners for development of its oncology portfolio
- 31 Jul 2003 Preclinical development for Alopecia (Chemotherapy-induced, Prevention)/Chemoprotection in USA (unspecified route)
- 31 Jul 2003 Preclinical development for Radiation injuries (Prevention)/Radioprotection in USA (unspecified route)